Company Overview

Sanara MedTech Inc. is a U.S.-based medical technology company focused on advanced wound care, surgical products, and regenerative medicine solutions. The company operates within the broader healthcare and medical devices industries, primarily serving hospitals, surgical centers, wound care clinics, long-term care facilities, and healthcare practitioners. Sanara develops, markets, and distributes products intended to support chronic wound healing, surgical recovery, and skin repair, with revenue generated through both internally developed products and distribution partnerships.

The company’s principal business lines include advanced biologics, wound care products, collagen-based technologies, antimicrobial solutions, and surgical tissue products. Key offerings include products marketed under brands such as CellerateRX, BIAKŌS Antimicrobial Skin & Wound Cleanser, and regenerative tissue products obtained through affiliated investments and partnerships. Sanara has evolved from a wound care-focused company into a broader regenerative medicine platform through acquisitions, strategic investments, and commercialization agreements. Public filings and investor materials indicate that the company’s strategy emphasizes high-growth specialty wound care segments and clinician-focused product adoption.

Business Operations

Sanara conducts operations primarily through its advanced wound care and regenerative medicine activities in the United States. The company generates revenue through direct sales, commercial distribution agreements, and licensing arrangements associated with wound and surgical care products. Its operations include commercialization of collagen products, antimicrobial wound solutions, and tissue-based regenerative products. The company also maintains relationships with healthcare distributors and specialty sales channels to expand product penetration in clinical settings.

Sanara controls or has interests in several technologies and commercial assets tied to biologic wound healing and surgical applications. Strategic relationships with entities such as Precision Healing Inc. and investments connected to regenerative medicine technologies have expanded its exposure to data-driven wound care management and biologic product development. Public disclosures also identify involvement with tissue-processing and advanced wound technologies through affiliated entities and investment holdings. The company’s operational footprint remains concentrated in the healthcare provider market, particularly among facilities managing chronic and post-surgical wounds.

Strategic Position & Investments

Sanara’s strategic direction centers on expanding its advanced wound care portfolio, increasing recurring product utilization, and strengthening its regenerative medicine capabilities. The company has pursued growth through acquisitions, minority investments, and commercialization partnerships aimed at broadening its clinical offerings. Management has emphasized physician engagement, evidence-based product positioning, and expansion into higher-margin biologic wound care segments as key growth priorities.

Major investments have included positions in regenerative medicine and wound analytics businesses, notably through involvement with Precision Healing Inc., a company focused on artificial intelligence-enabled wound imaging and analytics. Sanara has also invested in biologic tissue technologies and products associated with surgical healing and skin repair. Company filings indicate that these investments are intended to create a more integrated wound care ecosystem combining diagnostics, biologics, and clinical workflow support. Data regarding the long-term commercial impact of certain early-stage investments remains inconclusive based on available public sources.

Geographic Footprint

Sanara MedTech’s primary operational and commercial presence is in the United States, where it markets products to healthcare providers across hospital systems, outpatient wound centers, and post-acute care settings. The company is headquartered in Fort Worth, Texas, and its commercialization activities are concentrated within the domestic healthcare market. Public filings do not indicate a broad standalone international operating infrastructure comparable to larger multinational medical device firms.

Although the company’s direct operational footprint is largely domestic, some products and biologic technologies may involve manufacturing, sourcing, or distribution relationships with broader international components. Available public information suggests that Sanara’s current strategic emphasis remains focused on expanding penetration within the U.S. advanced wound care market rather than pursuing large-scale international expansion. Data regarding material direct international revenue exposure is limited in publicly available disclosures.

Leadership & Governance

Sanara MedTech’s leadership team combines healthcare operations, wound care commercialization, finance, and medical technology experience. The company’s governance structure reflects a focus on specialty healthcare growth and strategic investment execution within the advanced wound care sector. Public communications and filings emphasize disciplined capital allocation, expansion of regenerative medicine capabilities, and clinician-centered innovation as central elements of management strategy.

Key executives and leadership include:

• Michael J. Catelani – Chief Executive Officer
• Christopher J. Cashman – Chief Commercial Officer
• Kristie L. Burns – Chief Financial Officer
• Robert G. Orr – Executive Chairman

The company’s board and executive leadership have highlighted operational scalability, strategic partnerships, and product portfolio diversification as core priorities. Leadership commentary in investor presentations and regulatory filings consistently emphasizes building a differentiated wound care platform supported by biologics, data-enabled care technologies, and specialized clinical relationships.